EDMONTON, Alberta and TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- SNDL Inc. (Nasdaq: SNDL, CSE: SNDL) (“SNDL”) and 1CM Inc. (CSE: EPIC) (OTCQB: MILFF) (FSE: IQ70) (“1CM”) announce that they have entered into an amended and restated arrangement agreement (the “A&R Arrangement Agreement”) dated December 15, 2025. The A&R Arrangement Agreement amends and restates the arrangement agreement dated April 9, 2025 between 1CM and SNDL (the “Original Arrangement Agreement”), pursuant to which SNDL agreed to, among oth ...

智通财经APP获悉，周五，大麻股集体狂飙，Tilray Brands(TLRY.US)大涨超32%，canopy growth(CGC.US)涨超23%，SNDL(SNDL.US)涨超19%，极光大麻(ACB.US)涨超11%，cronos group(CRON.US)涨超5%。消息面上，多家美国当地媒体报道称，美国总统唐纳德.特朗普预计将推动把 大麻重新归类为"危害性较低的药物"。根据媒体报道，特朗普正在考虑将大麻从"附表I"(Schedule I) ——该类别表示无医疗用途且具有高滥用潜力——大幅度调整至"附表III"——这是一类依赖性与成瘾性 潜力较低的物质类别。 ...

The stock prices of major cannabis companies like Tilray Brands (NASDAQ:TLRY) and Canopy Growth (NASDAQ:CGC) skyrocketed 34.88% and 27.46%, respectively, in premarket trading on Friday, following reports of President Donald Trump‘s plans to relax federal regulations on marijuana. Meanwhile, Aurora Cannabis Inc. (NASDAQ:ACB) surged 20%, Cronos Group Inc. (NASDAQ:CRON) gained 19% and Organigram Global Inc. (NASDAQ:OGI), and SNDL Inc. (NASDAQ:SNDL) rose 12% and 34.7% respectively. Reclassification Of Cannabis ...

智通财经APP获悉，多家美国当地媒体报道称，美国总统唐纳德·特朗普预计将推动把大麻重新归类 为"危害性较低的药物"，这一最新的市场动态无疑直接推动美国大麻类生产商股票周五在美股盘前交易 中大幅上涨。涨幅居前的包括：Tilray Brands(TLRY.US)盘前大涨超30%，Canopy Growth(CGC.US)涨 23%，Aurora Cannabis(ACB.US)涨20%，SNDL(SNDL.US)涨14%，Cronos Group(CRON.US)涨12%。 根据媒体报道，特朗普正在考虑将大麻从"附表I"(Schedule I)——该类别表示无医疗用途且具有高滥用 潜力——大幅度调整至"附表III"——这是一类依赖性与成瘾性潜力较低的物质类别。 据报道，特朗普当地时间周四早些时候与美国众议院议长迈克·约翰逊、特朗普亲自提名的卫生与公众 服务部(HHS)部长小罗伯特·F·肯尼迪、医疗保险和医疗补助服务中心(CMS)署长梅赫梅特·奥兹，以及数 位大麻行业高管通话，讨论该事项。 不过报道称，联系到的一名白宫高级官员表示，特朗普本人尚未给出最终的行政决定。 附表III药物具有已被普遍接受的医疗用途，但仍存 ...

Core Viewpoint - Four cannabis stocks are showing significant technical momentum despite new regulatory challenges from Washington, particularly a provision in a government funding bill that could re-criminalize many hemp-derived THC products [1][2]. Group 1: Stock Performance - The stocks demonstrating gains include Tilray Brands Inc. (NASDAQ:TLRY), Cronos Group Inc. (NASDAQ:CRON), Organigram Global Inc. (NASDAQ:OGI), and SNDL Inc. (NASDAQ:SNDL) [2]. - Benzinga Edge's Stock Rankings indicate that all four companies exhibit strong positive momentum, particularly over the last six months [3]. - The six-month returns for the stocks are as follows: TLRY at 156.82%, CRON at 20.39%, OGI at 26.23%, and SNDL at 32.81% [4]. Group 2: Individual Stock Analysis - TLRY shows a weaker price trend in the short term but strong trends in medium and long terms, with a pre-market decline of 1.77% [6]. - CRON maintains a weaker short-term price trend but strong medium and long-term trends, with a pre-market increase of 3.63% [6]. - OGI has a weaker price trend in the short and medium terms but a strong long-term trend, with a pre-market decline of 1.95% [6]. - SNDL has a moderate growth ranking despite weaker trends across all timeframes, with a pre-market increase of 2.35% [6]. Group 3: Regulatory Environment - A new legislative provision in the funding package re-criminalizes intoxicating hemp products, which could significantly impact the market [7]. - Senator Rand Paul criticized the provision, stating it could eliminate nearly 100% of legal hemp products overnight, adversely affecting farmers [7]. - The regulatory changes may benefit multi-state operators by reducing "gray-market" competition but are expected to negatively impact Canadian companies like Tilray, which viewed the hemp-derived product segment as a key entry point into the U.S. market [8].

Core Viewpoint - Four cannabis stocks are showing significant technical momentum despite new regulatory challenges from Washington, particularly a provision in a government funding bill that could re-criminalize many hemp-derived THC products [1][2]. Group 1: Stock Performance - The stocks demonstrating gains include Tilray Brands Inc. (NASDAQ:TLRY), Cronos Group Inc. (NASDAQ:CRON), Organigram Global Inc. (NASDAQ:OGI), and SNDL Inc. (NASDAQ:SNDL) [2]. - Benzinga Edge's Stock Rankings indicate that all four companies exhibit strong positive momentum, particularly over the last six months [3]. - The six-month returns for the stocks are as follows: TLRY at 156.82%, CRON at 20.39%, OGI at 26.23%, and SNDL at 32.81% [4]. Group 2: Individual Stock Analysis - TLRY shows a weaker price trend in the short term but strong trends in medium and long terms, with a pre-market decline of 1.77% [6]. - CRON maintains a weaker short-term price trend but strong medium and long-term trends, with a pre-market increase of 3.63% [6]. - OGI has a weaker price trend in the short and medium terms but a strong long-term trend, with a pre-market decline of 1.95% [6]. - SNDL has a weaker price trend across all timeframes but a moderate growth ranking, with a pre-market increase of 2.35% [6]. Group 3: Regulatory Environment - A new legislative provision in the funding package re-criminalizes intoxicating hemp products, which could significantly impact the market [7]. - Senator Rand Paul criticized the provision, stating it could eliminate nearly 100% of legal hemp products overnight, adversely affecting farmers [7]. - The regulatory changes may benefit multi-state operators by reducing "gray-market" competition but are expected to negatively impact Canadian companies like Tilray, which had aimed to enter the U.S. market through hemp-derived products [8].

Core Insights - SNDL Inc. reported improved Q3-2025 results with increasing revenues and free cash flow for the quarter [1] - Despite the improvements, noncash impairments led to an overall net loss for the company [1] - The company's stock price has decreased by 22% over the last period [1] Financial Performance - The company experienced an increase in revenues during Q3-2025 [1] - Free cash flow also showed improvement for the quarter [1] - Noncash impairments negatively impacted the overall financial results, resulting in a net loss [1] Stock Market Reaction - SNDL's stock price has declined by 22% recently, indicating market concerns despite the positive revenue and cash flow trends [1]

Financial Data and Key Metrics Changes - SNDL reported net revenue of CAD 244 million for Q3 2025, reflecting a 3.1% increase year-over-year, driven primarily by the cannabis segments [7][10] - Gross profit reached CAD 64.2 million, a 1.9% increase year-over-year, despite CAD 3.9 million in non-cash inventory-related adjustments [8][9] - Free cash flow for the quarter was CAD 16.7 million, marking a CAD 7.5 million improvement compared to the same period last year, and achieving positive cumulative free cash flow of CAD 7.7 million for the first nine months of the year [10][13] Business Line Data and Key Metrics Changes - The liquor retail segment generated net revenue of CAD 139.4 million, a 3.6% year-over-year decline, while gross profit was CAD 36.7 million, a modest reduction of CAD 0.2 million [14][15] - Cannabis retail achieved net revenue of CAD 85 million, a record high with a 4.8% year-over-year growth, and gross profit of CAD 22.5 million, reflecting an 8.5% increase [16] - Cannabis operations reported net revenue of CAD 37.4 million, a 50% growth year-over-year, driven by edibles and international sales [17] Market Data and Key Metrics Changes - The cannabis retail segment saw a 3.6% increase in same-store sales, contributing to a 12 basis points gain in market share [19] - International sales reached CAD 4.2 million in Q3, with expectations for continued growth due to strong demand and reliability of supply [20][33] Company Strategy and Development Direction - SNDL is focused on growth, profitability, and enhancing its workforce, with plans to open five new cannabis stores and two new Wine & Beyond stores in Q4 [19][21] - The company aims to strengthen its competitive position in Canada while resolving ongoing litigation related to Sunstream restructurings, which are expected to provide exposure to dynamic medical markets [5][6] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of CAD 11.9 million in unfavorable non-cash items on the P&L, but emphasized operational improvements and cash generation as key indicators of business fundamentals [4][3] - The outlook for cannabis retail is mixed, with signs of market maturity in provinces like Alberta and Ontario, but opportunities for margin improvement remain [36][39] Other Important Information - SNDL has no debt and over CAD 240 million in unrestricted cash, providing a strong balance sheet to support growth initiatives [5] - The company is experiencing a significant increase in share-based compensation due to a 121% rise in share price during Q3 [9][12] Q&A Session Summary Question: Clarification on cannabis operations write-offs - Management confirmed CAD 3.9 million inventory adjustment impacting gross profit and CAD 2.7 million fixed asset impairment affecting operating income but not gross margin [25][27] Question: Growth drivers for sales to provincial boards - Management noted softness in third-party retail sales but continued growth in their own segment, with expectations for regaining momentum through new products and innovation [29][30] Question: International sales outlook - Management expressed optimism about international sales growth, with strong demand and increasing purchase orders anticipated for Q4 and beyond [32][33] Question: Update on 1CMPharm transaction regulatory approval - Management stated that the review process is ongoing, with no additional information available at this time [35] Question: Market opportunities in cannabis retail - Management indicated a shift towards maturity in the market, with expectations for low single-digit revenue growth moving forward, while also noting improvements in gross margin [36][39] Question: RISE rewards program performance - Management reported strong engagement from loyalty members and plans to roll out a similar program for the liquor business [41]

Disclaimer Forward-looking statements Certain statements contained in this presentation may constitute forward-looking information and statements. All statements in this presentation, other than statements of historical fact, that address events or developments concerning SNDL Inc. ("SNDL" or the "Company") that SNDL expects to occur are "forward-looking information and statements". Forward-looking information and statements are often, but not always, identified by the use of words such as "seek", "anticipa ...

Core Insights - SNDL Inc. reported strong financial results for Q3 2025, achieving record free cash flow and positive cumulative free cash flow for the first nine months of the year, indicating operational and profitability improvements [4][6][8] - The company maintains a strong balance sheet with no debt and $240.6 million in unrestricted cash, positioning it for growth and investment opportunities [5][6] Financial Performance - **Net Revenue**: In Q3 2025, net revenue was $244.2 million, a 3.1% increase from Q3 2024, driven by a 13.5% growth in the combined Cannabis business, partially offset by a decline in the Liquor retail segment [6][8][30] - **Gross Profit**: Gross profit reached $64.2 million, up 1.9% year-over-year, with a gross margin of 26.3%, reflecting a slight decrease of 0.3 percentage points [6][8][30] - **Operating Income**: The company reported an operating loss of $11.1 million, improved by 40.3% compared to the previous year, influenced by non-cash items and restructuring charges [6][8][30] - **Free Cash Flow**: Free cash flow hit a record $16.7 million, primarily due to a reduction in working capital, despite significant CAPEX investments [6][8][30] Business Segments - **Cannabis Retail**: Generated net revenue of $85.0 million, a 4.8% increase year-over-year, with operating income growing by 107.2% [18][21] - **Cannabis Operations**: Achieved a 49.5% increase in net revenue to $37.4 million, although it faced an operating loss due to inventory write-offs [20][27] - **Liquor Retail**: Experienced a decline in net revenue to $139.4 million, down 3.6% year-over-year, with same-store sales decreasing by 2.6% [15][16] Strategic Initiatives - The company is pursuing the acquisition of 32 cannabis retail stores from 1CM Inc. for $32.2 million, pending regulatory review [12] - SNDL is investing in organic growth with plans for five new Cannabis store openings and two new Wine & Beyond stores in Q4 2025 [12] - The company continues to restructure SunStream Bancorp Inc. to enhance shareholder exposure to medical cannabis markets [12][27] Investment Portfolio - As of September 30, 2025, SNDL's investment portfolio had a carrying value of $410.8 million, with a positive operating income of $1.5 million generated during the quarter [27] - The company realized a gain of $5.3 million from the partial sale of its equity position in High Tide Inc. [27]